N30 Pharmaceuticals Garners $20,000,000 New Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c911e35a-2f4d-4f78-94f0-67dd8906d885
Date
11/20/2014
Company Name
N30 Pharmaceuticals
Mailing Address
3122 Sterling Circle Boulder, CO 80301 USA
Company Description
N30 Pharmaceuticals, LLC is developing s-nitrosothiol therapies for important unmet needs in respiratory diseases. N30’s strategy focuses on administration of GSNO to the human airway, and development of small molecule inhibitors of GSNO reductase.
Website
http://www.n30pharma.com
Transaction Type
Venture Equity
Transaction Amount
$20,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Proceeds from the financing will primarily be used to advance the Company’s clinical trial program for N91115, a novel inhibitor S-nitrosoglutathione reluctase (GSNOR).
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor